We’re one of the most active investors in university and other research-based companies in the world, with a proven track-record in backing and nurturing science and technology-based businesses to deliver impact alongside returns.
Financial highlights
As at 30 June 2024
NAV per share
FY 2023: 114.8pps
Gross cash & deposits
FY 2023: £226.9m
Return on NAV
FY 2023: (13%)
We're one of the most active investors in university and other research-based companies in the world, with a proven track-record in backing and nurturing science and technology-based businesses to deliver a better future for people and planet.
Visit our Investment Showcase by Curation Connect to get an overview of our investment thesis, hear from our CEO, Greg Smith, directly, and find a curated summary of the publicly available investment content and literature relevant to IP Group.
Expertise
Impact is in our DNA: we’ve always been committed to backing and growing businesses that transform ideas into impact, at scale, for a healthier, tech-enriched, regenerative future. Our portfolio delivers positive social and environmental benefits and aligns well with the UN’s Sustainable Development Goals, concentrating on six in particular.
The companies we’ve backed have created more than 10,000 jobs.
Our network of relationships with advisers, investors, co-investors and partners around the world has been built up over many years.
Permanent capital structure
Investing from our balance sheet offers significant advantage when compared to fixed-life funds, as it means we can co-found companies, ‘follow our money’ through subsequent funding rounds and don’t need to sell our holdings on an artificial timescale due to a specific fund closing date. We know from experience that supporting early-stage science takes time and our structure allows us to be patient.
We’re the most active investor in the UK in our sector and the second most active in Europe.
Portfolio
We provide differentiated access to impactful dealflow and the best IP and ideas from our networks, universities and research institutions. This in turn offers investors exposure to an exciting portfolio of high-growth companies operating within the areas of life sciences, deeptech and cleantech.
Over 500 companies formed and supported across the Group.
Track record
We have a track record built over more than 20 years of turning great ideas into world-changing businesses and creating value.
*As at 31 Dec 2023
invested in science-based businesses*
cumulative realisations*
cumulative returns to shareholders since 2021*
unicorns created (Oxford Nanopore, Hinge Health, Ceres Power)*